Compare IBTA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBTA | FTRE |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.3M | 829.3M |
| IPO Year | 2024 | 2023 |
| Metric | IBTA | FTRE |
|---|---|---|
| Price | $32.07 | $13.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $28.50 | $14.06 |
| AVG Volume (30 Days) | 130.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $342,389,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $8.96 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $19.10 | $3.97 |
| 52 Week High | $55.63 | $18.67 |
| Indicator | IBTA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 57.90 |
| Support Level | $21.23 | $8.85 |
| Resistance Level | $35.11 | $18.26 |
| Average True Range (ATR) | 2.08 | 0.85 |
| MACD | -0.85 | -0.03 |
| Stochastic Oscillator | 29.26 | 52.51 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.